PDS BIOTECHNOLOGY CORPORATION Financials PDS Biotechnology Corporation
Equities
PDSB
US70465T1079
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.49 USD | -1.13% |
|
-0.57% | -29.78% |
| May. 15 | PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 10 | NetScientific says PDS Biotech's Versamune meets endpoints | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 14 | 47.64 | 230.3 | 376.3 | 154.6 | 128 | - | - |
| Enterprise Value (EV) 1 | 14 | 47.64 | 230.3 | 376.3 | 154.6 | 128 | 128 | 128 |
| P/E ratio | - | -2.4 x | -12.3 x | -9.23 x | -3.58 x | -2.9 x | -2.26 x | -2.92 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 349 x | 11.4 x |
| EV / Revenue | - | - | - | - | - | - | 349 x | 11.4 x |
| EV / EBITDA | -0.67 x | -3.2 x | -10.7 x | -9.03 x | -3.6 x | -3.42 x | -1.82 x | -2.37 x |
| EV / FCF | -0.77 x | - | - | -14.6 x | -4.6 x | -2.29 x | -1.97 x | -1.73 x |
| FCF Yield | -129% | - | - | -6.83% | -21.8% | -43.7% | -50.8% | -57.8% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 5,281 | 22,262 | 28,438 | 28,509 | 31,108 | 36,679 | - | - |
| Reference price 2 | 2.650 | 2.140 | 8.100 | 13.20 | 4.970 | 3.490 | 3.490 | 3.490 |
| Announcement Date | 3/27/20 | 3/18/21 | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.3667 | 11.25 |
| EBITDA 1 | -20.94 | -14.89 | -21.43 | -41.67 | -42.99 | -37.47 | -70.25 | -54 |
| EBIT 1 | -21.03 | -14.9 | -21.44 | -41.67 | -43.05 | -42.84 | -54.97 | -58.92 |
| Operating Margin | - | - | - | - | - | - | -14,992.79% | -523.7% |
| Earnings before Tax (EBT) 1 | - | -14.85 | -21.43 | -42.05 | -44.35 | -44.94 | -67.43 | -57.25 |
| Net income 1 | - | -14.85 | -16.92 | -40.85 | -42.94 | -44.94 | -64.19 | -57.25 |
| Net margin | - | - | - | - | - | - | -17,506.39% | -508.89% |
| EPS 2 | - | -0.8900 | -0.6600 | -1.430 | -1.390 | -1.205 | -1.545 | -1.193 |
| Free Cash Flow 1 | -18.07 | - | - | -25.71 | -33.64 | -55.96 | -64.99 | -73.94 |
| FCF margin | - | - | - | - | - | - | -17,725.34% | -657.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/27/20 | 3/18/21 | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -6.321 | -8.479 | -7.093 | -7.279 | -18.82 | -9.419 | -12.69 | -10.51 | -10.39 | - | -9.125 | -9.125 | -9.125 |
| EBIT 1 | -6.322 | -8.479 | -7.093 | -7.279 | -18.82 | -9.422 | -12.7 | -10.52 | -10.41 | -10.1 | -10.11 | -10.71 | -11.96 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.32 | -8.474 | -7.018 | -7.424 | -19.14 | -9.66 | -12.94 | -10.85 | -10.9 | -10.6 | -10.56 | -11.21 | -12.56 |
| Net income 1 | -6.32 | -8.474 | -5.819 | -7.424 | -19.14 | -9.66 | -11.53 | -10.85 | -10.9 | -10.6 | -10.74 | -13.05 | -13.54 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2300 | -0.3200 | -0.2000 | -0.2600 | -0.6700 | -0.3200 | -0.3700 | -0.3500 | -0.3500 | -0.3000 | -0.3033 | -0.3300 | -0.3167 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/11/22 | 8/8/22 | 11/14/22 | 3/28/23 | 5/15/23 | 8/14/23 | 11/14/23 | 3/27/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -18.1 | - | - | -25.7 | -33.6 | -56 | -65 | -73.9 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | 0.8 | 0.8 | 0.8 |
| Capex / Sales | - | - | - | - | - | - | 218.18% | 7.11% |
| Announcement Date | 3/27/20 | 3/18/21 | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.49
USD
Average target price
13
USD
Spread / Average Target
+272.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.78% | 128M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.68% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- PDSB Stock
- Financials PDS Biotechnology Corporation
